Genentech buys Regor’s CDK inhibitors in $850m deal
Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
emjreviews.com8h
Genentech acquires Regor’s next-gen CDK inhibitor portfolio
Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...
pharmaphorum14h
Ensuring compliance - The Functional Point of Contact (FPOC) story
As has been widely acknowledged, one of the most meaningful steps a business can take is to establish a single point of ...
Pharmabiz18h
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...